Researchers Get Closer to Preventing Alzheimer’s Disease

	Tweet

A recent study directed by Mount Sinai School of Medicine identifies a faulty molecule in the brain found in cases of mild cognitive impairment (MCI). Researchers say this faulty molecule may be responsible for the progression of MCI to mild Alzheimer’s disease (AD) dementia. The study, which appeared June 10th online in the journal Neurobiology of Aging, may lead to preventative treatments for AD.

An estimated 4.5 million Americans have Alzheimer’s disease and presently there are no known cures or effective preventive strategies.

“Alzheimer’s Disease is a growing health concern that affects millions of people, “says Giulio Maria Pasinetti, M.D., Ph.D., Professor of Psychiatry and Neuroscience, Director of the Neuroinflammation Research Center at Mount Sinai School of Medicine and lead author of the study. “We hope our research provides direction for preventative treatments to delay the onset of AD dementia by eliminating amyloid plaque-causing peptides in the brain.”

People with AD exhibit elevated levels of beta-amyloid peptides that cause plaque buildup in the brain (the main characteristic of AD). In the earliest stages of Alzheimer’s, beta-amyloid peptides are on the rise, especially in the two connected brain regions critical for memory functions-- the hippocampus and entorhinal cortex.

In this study, Dr. Pasinetti and colleagues at Mount Sinai School of Medicine in New York suggests one reason for that early increase of beta-amyloid peptides: an enzyme that breaks down beta-amyloid peptides, also referred to as an insulin-degrading enzyme (IDE), is not active in the brain in the cases at high-risk for developing AD. To assess possible changes in IDE during MCI, the investigators measured protein levels and enzymatic activity in postmortem brain tissue from 46 elderly subjects.

Implications
A loss of IDE activity has been previously shown to occur in severe AD dementia, and the current results raise the possibility that a deficit in degradation of amyloid peptides from IDE could raise levels of toxic beta-amyloid peptides even before AD dementia is diagnosed. If these results are confirmed, Mount Sinai researchers suggest that boosting IDE activity pharmacologically may reverse beta-amyloid peptide accumulation. This new finding may provide a pharmacological therapeutic angle to preventing AD dementia.

Dr. Pasinetti and colleagues also measured levels of beta-amyloid peptides in the entorhinal cortex and found that the amount of beta-amyloid was inversely correlated with IDE activity they measured in the hippocampus. These results support the idea that alterations in IDE might be causally related to beta-amyloid peptides accumulation, starting in the earliest stages of AD.

Mount Sinai School of Medicine

RELATED STORIES:
Guideline: Kids with Small Head Size at Risk of Neurologic Problems, Screening Needed   MRI may contribute to early detection of Alzheimer’s   Anger or startling event may trigger stroke   Memory Training Might Not Be Best for Reducing “Senior Moments”   Study finds shingles may be related to elevated risk of multiple sclerosis   Sleep position may cause apnea in stroke patients   Blood vessel condition tied to MS, with caveats   Gene Discovery Aids Understanding of Neurological Disorder   Canadian boy who was treated in U.S. dies in Ontario   Stroke awareness campaign aims to halve deaths   Mayo Clinic Finds Tool to Predict Disability Timeline for Progressive MS Patients   New Tool Can Help Predict Risk of Alzheimer’s in Elderly

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]